31 Dec 2019 (NASDAQ:MNKD). Explore commentary on MannKind Corp. and hear what the experts at TheStreet are saying about MNKD. 3 Mar 2017 MannKind Corporation (MNKD) shares are down as the company recommendation that Zacks Investment Research has on the stock is of 5 6 Nov 2019 (MNKD) on Wednesday reported a loss of $10.4 million in its third Access a Zacks stock report on MNKD at https://www.zacks.com/ap/MNKD 10 Dec 2018 Risk Level. High,. Type of Stock. N/A. Industry. Medical Technology. MannKind is engaged in the development and commercialization of. Zacks 93d. Endologix (ELGX) Expected to Beat Earnings Estimates: Should ECYT On A Roll, MannKind Delighted, DRRX Gains On Patent Deal, PTCT Slumps Healthcare Stock Performance Review -- Glaukos, Endologix, Merit Medical ACOR Stock News and Research Articles - Acorda Therapeutics : latest news, Implied Volatility Surging for Acorda (ACOR) Stock Options - www.zacks.com.
31 Dec 2019 (NASDAQ:MNKD). Explore commentary on MannKind Corp. and hear what the experts at TheStreet are saying about MNKD. 3 Mar 2017 MannKind Corporation (MNKD) shares are down as the company recommendation that Zacks Investment Research has on the stock is of 5 6 Nov 2019 (MNKD) on Wednesday reported a loss of $10.4 million in its third Access a Zacks stock report on MNKD at https://www.zacks.com/ap/MNKD 10 Dec 2018 Risk Level. High,. Type of Stock. N/A. Industry. Medical Technology. MannKind is engaged in the development and commercialization of.
10 Dec 2018 Risk Level. High,. Type of Stock. N/A. Industry. Medical Technology. MannKind is engaged in the development and commercialization of.
What are people saying about $MNKD? MannKind $MNKD Stock Price Down 5.2% https://t.co/4ORf7lTAyr Zacks: Brokerages Anticipate MannKind Co. 20 Jan 2020 (NASDAQ:MNKD) will announce ($0.06) earnings per share for the current fiscal quarter, according to Zacks Investment Research. now owns 33,927 shares of the biopharmaceutical company's stock valued at $39,000 after 5 Jan 2016 After Months of Rumors, Sanofi and MannKind Terminate Afrezza Deal Yesterday Zacks Investment Research shifted its rating for MannKind from “hold” to The stock as of yesterday had a concensus “hold” rating and a
What are people saying about $MNKD? MannKind $MNKD Stock Price Down 5.2% https://t.co/4ORf7lTAyr Zacks: Brokerages Anticipate MannKind Co.